Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811551 | 0.90 | ALOX5AP (0.60) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9520741 | 0.83 | ALOX5AP (0.52) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9522220 | 0.80 | ALOX5AP (0.49) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9043392 | 0.80 | ALOX5AP (0.43) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9521164 | 0.79 | ALOX5AP (0.50) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9388578 | 0.79 | ALOX5AP (0.52) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9387633 | 0.78 | ALOX5AP (0.51) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9388581 | 0.78 | ALOX5AP (0.52) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1806837 | 0.77 | PTGES (0.47) | ALOX5APALOX5CYP3A4CYP2C9PTGS2 | |
| SCHEMBL2107856 | 0.76 | ALOX5AP (0.60) | ALOX5APALOX5CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947942-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | Accelalox, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007022427-A9 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-2563359-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | Allergan, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011137363-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-1572185-A4 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1947942-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | Accelalox, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008055317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | THE UNIVERSITY OF SYDNEY (AU) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007022427-A9 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1572185-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | Insmed Incorporated (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004058240-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-1995024894-A9 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | — | 1995-10-26 | — | — | WO | disclosed |